- Home
- WAFD vs ARQT Comparison
WAFD vs ARQT Comparison
Compare WAFD & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WAFD | ARQT |
|---|---|---|
| Founded | 1917 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.2B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WAFD | ARQT |
|---|---|---|
| Price | $30.85 | $27.33 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $35.00 | $34.00 |
| AVG Volume (30 Days) | 1.3M | ★ 2.4M |
| Earning Date | 04-16-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | 5.20 | ★ 88.79 |
| EPS | ★ 2.45 | 0.03 |
| Revenue | $29,650,000.00 | ★ $376,072,000.00 |
| Revenue This Year | N/A | $34.85 |
| Revenue Next Year | $4.15 | $29.39 |
| P/E Ratio | ★ $12.79 | $898.17 |
| Revenue Growth | 7.79 | ★ 91.34 |
| 52 Week Low | $26.31 | $18.62 |
| 52 Week High | $39.49 | $31.77 |
Technical Indicators
Market Signals| Indicator | WAFD | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 23.21 | 59.00 |
| Support Level | $29.68 | $24.91 |
| Resistance Level | $33.78 | $28.18 |
| Average True Range (ATR) | 0.71 | 1.42 |
| MACD | -0.18 | 0.35 |
| Stochastic Oscillator | 11.51 | 80.73 |
Price Performance
Historical ComparisonAbout WAFD WaFd Inc.
WaFd Inc is engaged in providing lending, depository, insurance, and other banking services to consumers, mid-sized to large businesses, and owners and developers of commercial real estate. Through the WaFd Bank, it is involved in accepting deposits from the general public and investing these funds in loans of various types, including first-lien mortgages on single-family dwellings, construction loans, land acquisition and development loans among others. The Bank also invests in certain United States government and agency obligations along with other investments and also performs insurance brokerage activities. Geographically, it operates in Washington, Oregon, Idaho, Arizona, Utah, Nevada, New Mexico, California and Texas.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.